KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
about
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.MicroRNA binding site polymorphisms as biomarkers in cancer management and research.A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men.Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.
P2860
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
@en
type
label
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
@en
prefLabel
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.
@en
P2860
P50
P1476
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer
@en
P2093
Alessandro Buda
P2860
P304
P577
2012-04-21T00:00:00Z